net dbt
asset good price rais po
announc acquisit
morn announc agreement acquir biopharma
busi ge life scienc net purchas price
expect tax benefit cash price ge biopharma lead provid
instrument consum softwar biolog product manufactur
repres ebitda in-lin current ev/ebitda
multipl lst peer fact court ge discuss
press link surpris although valuat less
specul given unit higher organ sale growth margin adj ebitda
profil deal expect close see limit regulatori risk
good strateg fit fast grow market
estim busi sale growth y/i
recur consum revenu includ downstream
bioprocess hardwar consum servic annual growth
upstream bioprocess cell cultur media single-us develop
growth product lab filtrat genom consum grow
lsd/msd expect sustain y/i growth see deal good strateg fit
significantli enhanc posit life scienc market shown
tabl bioprocess market rel concentr given regul natur
market would expect near-term share shift make
competit futur given expand portfolio product servic
deal close accret yr yr
plan use combin equiti debt debt
blend rate financ deal first year post close see cent
accret adj ep year five adj ep accret expect
despit alreadi high margin ge busi benefit applic dhr
db platform greater focu busi management see annual cost
save ge first three year year appear
conserv given carve-out natur deal up-front one-tim cost
get unit oper stand-alon compani within dhr life scienc
segment expect high-singl digit year
dental spin ipo rais po
also announc dental spin ipo wherein sell
dentalco mid-to-l plan updat model later date
gain detail estim pro forma ebitda around
ebitda adjust dentalco ebitda addit ge
biopharma unit revenu synergi given acceler organ revenu
growth profil compani due pend acquisit higher growth ge
busi ipo lower growth dental unit chang could add
growth overal compani rais po base
estim pro forma ebitda new new
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
bofa merril lynch global research estim frost sullivan compani report
po base approxim ev/ebitda back
dcf analysi assum wacc termin growth rate multipl
premium compani lst broader healthcar peer group line
five year histor valuat believ justifi given margin-
expans potenti opportun capit deploy superior manag team
strong track record exist industri investor base
risk po fx risk econom risk cyclic exposur reduct
fund custom consolid slow bioprocess demand competit risk
risk either dental ipo pend acquisit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current januari later date indic
equiti invest rate distribut industrials/multi-industri group dec
equiti invest rate distribut global group dec
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
total return expect within period date initi rate
rate dispers guidelin coverag cluster
rate dispers may vari time time bofa merril lynch research believ better reflect invest prospect stock coverag cluster
incom rate indic potenti cash dividend same/high dividend consid secur same/low dividend consid secur pay
cash dividend coverag cluster compris stock cover singl analyst two analyst share common industri sector region classif stock
coverag cluster includ recent bofa merril lynch report referenc stock
price chart secur referenc research report avail http //pricechart baml com call mail
mlpf one affili act market maker equiti secur recommend report
issuer within last month invest bank client mlpf and/or one affili
mlpf affili receiv compens issuer non-invest bank servic product within past month
issuer within last month non-secur busi client mlpf and/or one affili
mlpf affili receiv compens invest bank servic issuer within past month
mlpf affili expect receiv intend seek compens invest bank servic issuer affili issuer within next three month
mlpf togeth affili benefici own one percent common stock issuer report issu day month reflect
ownership posit last day previou month report issu day month reflect ownership posit end second month preced date
report
mlpf one affili will sell buy client equiti secur issuer princip basi
issuer within last month secur busi client non-invest bank mlpf and/or one affili
bofa merril lynch research personnel includ analyst respons report receiv compens base upon among factor overal profit america
corpor includ profit deriv invest bank analyst respons report may also receiv compens base upon among factor overal
profit bank sale trade busi relat class secur financi instrument analyst respons
